

NOTIFICATION PURSUANT TO
SECTION 6 OF DSHEA

6 3 0 3 '98 SEP 21 P1 54

In compliance with Section 6 of the Dietary Supplement Health Education Act (DSHEA) and Rule 21 C.F.R. 101.93, this Notification is filed on behalf of the following manufacturer of **Schiff® Ostivone™ Ipriflavone Product #12841** bearing the statements set out below:

Weider Nutrition International., Inc.
2002 South 5070 West
Salt Lake City, Utah 84104

RECEIVED
9/15/98

The text of each structure-function claim for **Ipriflavone** is as follows:

- (Statement 1) Ipriflavone is a bioflavonoid shown to minimize the loss of bone mass and nutritionally support bone density. Ipriflavone supports osteoblast cells (also known as bone-forming cells) that utilize calcium to make new bone.
- (Statement 2) Ipriflavone is a bioflavonoid shown to minimize the loss of bone mass and nutritionally support bone density.
- (Statement 3) Ipriflavone supports osteoblast cells (also known as bone forming cells) which utilize calcium to make new bone.
- (Statement 4) Numerous clinical studies have shown Ipriflavone may significantly increase bone density in post-menopausal women with low bone mineral density.
- (Statement 5)

I, Luke R. Bucci, Ph.D., CCN, CNS, Vice President of Research at Weider Nutrition International., Inc. am authorized to certify this Notification of behalf of the Company. I certify that the information presented and contained in this Notification is complete and accurate and that the Office of Regulatory Affairs at Weider Nutrition International, Inc. has substantiation that each statement is truthful and not misleading.

DATED this 8th day of September, 199 8.

WEIDER NUTRITION INTERNATIONAL, INC.

BY:

LSR Bucci
DR. LUKE R. BUCCI
Vice President of Research